Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Atypical teratoid rhabdoid tumour (AT/RT)

A SMARCB1-deficient brain tumour of infants and young children: EZH2 inhibition and intensive chemotherapy.

Live from ClinicalTrials.gov + PubMed, fetched 2026-11-12 07:21 UTC. Every row links to its source record.

Principal investigators and study chairs named on the registry for atypical teratoid rhabdoid tumour (at/rt), ranked by a published score: 3 per Phase 2+ trial they lead, 1 per other trial role, 2 per oral or late-breaking talk and 0.5 per poster in our verified 2026 meeting rows, each halved every 24 months. Paper authorship is not scored yet. PubMed counts are author name plus indication, for the top 12; names are as the registry spells them, so a common name can pool several people. Open a row for their trials and links to their papers.

Ashley Margol

Children's Hospital Los Angeles

score 2.6

11 papers

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT07447076 · Sabine Mueller, MD, PhD · Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

Giselle Saulnier Sholler

Penn State Health Children's Hospital

score 2.5

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT06465199 · Milton S. Hershey Medical Center · Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Jordan Milner

University of Florida

score 2.3

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.3 = 2.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT06625190 · University of Florida · Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

David Steffin

Baylor College of Medicine

score 2.1

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.1 = 0 leading Phase 2+ trials + 2.1 other trial roles + 0 talks + 0 posters. 0 of 4 trials are Phase 2+.

Michael Ortiz

Memorial Sloan Kettering Cancer Center

score 1

5 papers

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1 = 1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT05985161 · Memorial Sloan Kettering Cancer Center · A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Jasia Mahdi

Baylor College of Medicine

score 1

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 2 trials are Phase 2+.

Susan Chi

Dana-Farber Cancer Institute

score 0.9

18 papers

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07390539 · Robbie Majzner · B7-H3.CD28Z.CART in CNS Neoplasms

Mary F Wedekind Malone

Pediatric Early Phase Clinical Trial Network

score 0.8

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.8 = 0.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT05286801 · National Cancer Institute (NCI) · Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Nilay Shah

Nationwide Children's Hospital

score 0.7

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.7 = 0.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT05135975 · Nationwide Children's Hospital · A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Colleen Annesley

Seattle Children's Hospital

score 0.7

1 papers

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.7 = 0 leading Phase 2+ trials + 0.7 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07148050 · Seattle Children's Hospital · Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

Corinne Summers

Seattle Children's Hospital

score 0.7

1 papers

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.7 = 0 leading Phase 2+ trials + 0.7 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07148050 · Seattle Children's Hospital · Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

Katherine Ryan

Stanford University

score 0.7

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.7 = 0 leading Phase 2+ trials + 0.7 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07087002 · Stanford University · GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

Premal Lulla

Baylor College of Medicine

score 0.6

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0 leading Phase 2+ trials + 0.6 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT06198296 · Baylor College of Medicine · Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Sara Federico

St. Jude Children's Research Hospital

score 0.5

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.5 = 0.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT04901702 · St. Jude Children's Research Hospital · Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Brian Rood

Children's National Research Institute

score 0.5

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.5 = 0 leading Phase 2+ trials + 0.5 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT06193759 · Children's National Research Institute · Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

Andrea T Franson

Children's Oncology Group

score 0.4

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.4 = 0.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04320888 · National Cancer Institute (NCI) · Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Christine A Pratilas

Children's Oncology Group

score 0.4

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.4 = 0.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04284774 · National Cancer Institute (NCI) · Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Elizabeth D Alva

Children's Oncology Group

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04195555 · National Cancer Institute (NCI) · Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Suzanne Forrest

Dana-Farber Cancer Institute

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04416568 · Dana-Farber Cancer Institute · Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Christopher DeRenzo

St. Jude Children's Research Hospital

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05835687 · St. Jude Children's Research Hospital · Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Giedre Krenciute

St. Jude Children's Research Hospital

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05835687 · St. Jude Children's Research Hospital · Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Kelsey Bertrand

St. Jude Children's Research Hospital

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05835687 · St. Jude Children's Research Hospital · Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Alice Lee

Children's Oncology Group

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03210714 · National Cancer Institute (NCI) · Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Kieuhoa T Vo

Children's Oncology Group

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03698994 · National Cancer Institute (NCI) · Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Meredith S Irwin

Children's Oncology Group

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03213652 · National Cancer Institute (NCI) · Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Rajen Mody

Children's Oncology Group

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03526250 · National Cancer Institute (NCI) · Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Tian Zhang

Alliance for Clinical Trials in Oncology

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph3NCT03793166 · National Cancer Institute (NCI) · Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Chris DeRenzo

St. Jude Children's Research Hospital

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0 leading Phase 2+ trials + 0.2 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT04897321 · St. Jude Children's Research Hospital · B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Tannaz Armaghany

Baylor College of Medicine

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0 leading Phase 2+ trials + 0.2 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05103631 · Baylor College of Medicine · Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

Donald W Parsons

Children's Oncology Group

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03155620 · National Cancer Institute (NCI) · Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Katherine A Janeway

Children's Oncology Group

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03213704 · National Cancer Institute (NCI) · Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Susan N Chi

Children's Oncology Group

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03213665 · National Cancer Institute (NCI) · Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Theodore W Laetsch

Children's Oncology Group

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03213678 · National Cancer Institute (NCI) · Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Thomas Cash

Emory University

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT02574728 · Emory University · Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

Bilal Omer

Baylor College of Medicine

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT04099797 · Baylor College of Medicine · C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

Catherine Albert

Seattle Children's Hospital

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT04483778 · Seattle Children's Hospital · B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Gregory Friedman

M.D. Anderson Cancer Center

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT03911388 · M.D. Anderson Cancer Center · HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Jarrod Longcor

Cellectar Biosciences

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT03478462 · Cellectar Biosciences, Inc. · Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

Juliane Gust

Seattle Children's Hospital

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT03638167 · Seattle Children's Hospital · EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

Katie Albert

Seattle Children's Hospital

score 0.1

–

Profile: all trials, NIH grants and most cited papers →Papers in atypical teratoid rhabdoid tumour (at/rt) (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.1 = 0 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT03618381 · Seattle Children's Hospital · EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults